Effects of Metoclopramide on Feeding Intolerance among Preterm Neonates; A Randomized Controlled Trial

Mirhadi Mussavi1, Khairollah Asadollahi2, Ghobad Abangah3

  • 1Department of Pediatrics, Faculty of Medicine, Tabriz University of Medicine, Tabriz.

Insights

Intravenous metoclopramide significantly reduced time to full enteral feeding and withheld feedings in preterm neonates with feeding intolerance. This study found no adverse effects, suggesting metoclopramide is a safe treatment option.

Area of Science:

  • Neonatal Medicine
  • Clinical Pharmacology
  • Pediatric Gastroenterology

Background:

  • Feeding intolerance is a common complication in preterm neonates.
  • Effective management strategies are crucial for improving outcomes in this vulnerable population.

Purpose of the Study:

  • To assess the efficacy and safety of intravenous metoclopramide for treating feeding intolerance in preterm neonates (less than 36 weeks gestational age).

Main Methods:

  • A randomized, controlled, masked cross-over study design.
  • Participants received either intravenous metoclopramide or placebo before feeding.
  • Key outcomes included time to full enteral feeding, adverse events, hospital stay, and incidence of necrotizing enterocolitis (NEC) or septicemia.

Main Results:

  • Metoclopramide group achieved full enteral feeding significantly faster (12.9±5.6 days) than the placebo group (17.0±6.3 days).
  • The number of withheld feedings was significantly lower in the metoclopramide group.
  • Regression analysis indicated metoclopramide use was associated with improved feeding parameters and no observed adverse effects.

Conclusions:

  • Intravenous metoclopramide may be a beneficial treatment for facilitating enteral feeding in preterm neonates with feeding intolerance.
  • The drug demonstrated a favorable safety profile in this study population.
Abstract

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
1.8K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
851
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
910
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K